❉ Buffybot wonderful businesses, fair prices

← back

VTRS Viatris

pharma · 2026-10-06

N/A
too hard · 26
Owner-earnings value$22.80
Price$17.62
Margin of safety +29.4%

Quality gate · 26/100

Returns on capital 0/30
Consistency 7.0/22
Margins / pricing power 10.0/16
Balance sheet 0/16
Cash conversion 3.3/10
Capital allocation 5.6/6

⚠ sub-hurdle returns (median roic 1% < 9%) · over-levered (net debt/EBITDA 5.1x > 4x) · unprofitable in too many years

Median ROIC0.7%
Gross margin34.8%
Net debt / EBITDA5.1x
Share count / yr-1.8%
Profitable years2/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)1.81B
Owner-earnings yield9.0%
Free-cash-flow yield9.0%
Growth used (normalized)-0.4%
Market-implied growth (reverse DCF)-6.4%
Terminal growth3.0%
Discount rate (hurdle)9.2%

Projected owner earnings

YrOwner earningsGrowthPV
11.80B -0.4%1.65B
21.80B -0.0%1.51B
31.81B 0.3%1.39B
41.82B 0.7%1.28B
51.84B 1.1%1.19B
61.87B 1.5%1.10B
71.91B 1.9%1.03B
81.95B 2.2%965.55M
92.00B 2.6%907.60M
102.06B 3.0%856.29M

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~-6%/yr owner-earnings growth over 10y (reverse DCF); model credits -0%. Capped at market + 6pts.

History

DateQualityPriceValueMoSRating
2026-10-06 26 $17.62 $22.80 +29.4% N/A
2026-09-02 26 $16.63 $21.58 +29.8% N/A
2026-07-31 26 $17.76 $21.50 +21.1% N/A
2026-07-02 26 $16.18 $20.96 +29.6% N/A
2026-06-25 26 $15.93 $20.64 +29.6% N/A
2026-06-23 26 $15.75 $21.50 +36.5% N/A